Novavax (NVAX) Reports Q4 EPS of ($11.28), Guides 2022 Revenue of $4-$5B
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.70 -2.9%
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Loss from operations: -63.31M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q4 EPS of ($11.28), $10.73 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $222 million versus the consensus estimate of $442.77 million.
GUIDANCE:
Novavax sees FY2022 revenue of $4-5 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
Create E-mail Alert Related Categories
Corporate News, Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
